Overview
NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.
Last reviewed: 27 January 2026
Next review: We will review this decision if the company decides to make a submission.